肺癌的分子生物学预后因素研究进展(5)
14.Brabender,J, Danenberg,D,Metzger,-REpidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival Clin-Cancer-Res. 2001 Jul 7(7): 1850-5.
15.Volm,M,Rittgen,-W. Cellular predictive factors for the drug response of lung cancer.Anticancer-Res. 2000 Sep- Oct 20(5B): 3449-58
16.Yuan-A,Yu,C,Chen,-W-J.Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int-J-Cancer. 2000 Nov 20,89(6): 475-83
, 百拇医药
17.Stockhammer-G,Obwegeser-A,Kostron,-H.Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression.Acta-Neuropathol-(Berl). 2000 Jul 100(1): 101-5.
18.Fontanini G,Vignati S,Bigini D,et al.Epidermal growth factor receptor(EGFR) expression in non-small cell lung carcinomas correlates with metastic involvement of hilar and medisstinal lymph nodes in the squamous subtypes.Eur J Cancer,1996,32A(2):178-183.
, 百拇医药
19.D'amico TA,Aloia TA,Moore MB,et al.Molecular biologic substaging of stage I lung cancer according to gendar and histology.Ann Thorac Sure,2000,49(2):101-108.
20.Pfeiffer P,Nexo E,Bentzen SM,et al.Enzyme linked immunosorbent assays of EGFRin lung cancer:comparisons with immunohistochemistry,clinicopathalogical features and prognosis.Br J cancer,1999,78(1):96-99.
21.Ylisirnio,-S, Hoyhtya-M,Turpeenniemi.Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Anticancer-Res. 2000 Mar-Apr 20(2B): 1311-6
, 百拇医药
22.Brambilla C,Brambilla E.Lung tumors,Fundamental biology and clinical management New York:Marcel Dekker Inc,1999,139-156.
23.Nisman-B,Amir-G,Lafair.Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer-Res. 1999 Jul-Aug19(4C): 3549-52
24.Cristofori,-R,Aimo,-G,Mengozzi,-G.Tumor markers kinetic in malignant lung neoplasms. J-Cardiovasc-Surg-(Torino). 1999 Apr- 40(2): 299-305
, http://www.100md.com
25.Yanagi-S,Sugiura-H,Morikawa-T.Tumor size does not have prognostic significance in stage Ia NSCLC. Anticancer-Res. 2000 Mar-Apr20(2B): 1155-8
26.Pelletier,-M,Edwardes-M,Michel,-R. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can-J-Surg. 2001 Jun- 44(3): 180-8
27.Kwiatkowski DJ,Harpole DH,Godleski J.Molecular pathologic substaging in 244stage non-small-cell lung cancer patients:clinical implications.J clin Oncol.1998,16(7):2468-77., http://www.100md.com(程超)
15.Volm,M,Rittgen,-W. Cellular predictive factors for the drug response of lung cancer.Anticancer-Res. 2000 Sep- Oct 20(5B): 3449-58
16.Yuan-A,Yu,C,Chen,-W-J.Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int-J-Cancer. 2000 Nov 20,89(6): 475-83
, 百拇医药
17.Stockhammer-G,Obwegeser-A,Kostron,-H.Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression.Acta-Neuropathol-(Berl). 2000 Jul 100(1): 101-5.
18.Fontanini G,Vignati S,Bigini D,et al.Epidermal growth factor receptor(EGFR) expression in non-small cell lung carcinomas correlates with metastic involvement of hilar and medisstinal lymph nodes in the squamous subtypes.Eur J Cancer,1996,32A(2):178-183.
, 百拇医药
19.D'amico TA,Aloia TA,Moore MB,et al.Molecular biologic substaging of stage I lung cancer according to gendar and histology.Ann Thorac Sure,2000,49(2):101-108.
20.Pfeiffer P,Nexo E,Bentzen SM,et al.Enzyme linked immunosorbent assays of EGFRin lung cancer:comparisons with immunohistochemistry,clinicopathalogical features and prognosis.Br J cancer,1999,78(1):96-99.
21.Ylisirnio,-S, Hoyhtya-M,Turpeenniemi.Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Anticancer-Res. 2000 Mar-Apr 20(2B): 1311-6
, 百拇医药
22.Brambilla C,Brambilla E.Lung tumors,Fundamental biology and clinical management New York:Marcel Dekker Inc,1999,139-156.
23.Nisman-B,Amir-G,Lafair.Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer-Res. 1999 Jul-Aug19(4C): 3549-52
24.Cristofori,-R,Aimo,-G,Mengozzi,-G.Tumor markers kinetic in malignant lung neoplasms. J-Cardiovasc-Surg-(Torino). 1999 Apr- 40(2): 299-305
, http://www.100md.com
25.Yanagi-S,Sugiura-H,Morikawa-T.Tumor size does not have prognostic significance in stage Ia NSCLC. Anticancer-Res. 2000 Mar-Apr20(2B): 1155-8
26.Pelletier,-M,Edwardes-M,Michel,-R. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can-J-Surg. 2001 Jun- 44(3): 180-8
27.Kwiatkowski DJ,Harpole DH,Godleski J.Molecular pathologic substaging in 244stage non-small-cell lung cancer patients:clinical implications.J clin Oncol.1998,16(7):2468-77., http://www.100md.com(程超)